Register for webinar 4

Webinar details

May 12, 2026 | 10:00am EST

Webinar overview

In this exclusive analyst briefing, we dissect the clinical and commercial trajectories of three pivotal innovations featured in our Drugs to Watch report:

• Gedatolisib, a PI3K/mTOR inhibitor for breast cancer
• INLEXZO (TAR-200), intravesical administration of gemcitabine for bladder cancer
• Relacorilant, a selective glucocorticoid receptor antagonist (SGRA) for ovarian cancer

Secure your spot to gain critical foresight into pivotal clinical data, competitive differentiation versus current standards of care, and the long-term market implications for these therapies.

Speakers

Michael Ward (Host)

Head of Global Thought Leadership, Clarivate

As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. His actionable insights and analysis support pharma, biotech, healthcare and medtech stakeholders gain a deeper understanding of market news and trends.

Arshiya Bhatt

Ph.D., Senior Healthcare Research & Data Analyst, Oncology

Dr. Bhatt combines over a decade of experience across academic research and industry, translating complex scientific data into insights across the oncology landscape. Prior to joining Clarivate, she worked as a Solution Scientist at Merck, where she led strategic collaborations, developed tailored scientific solutions and conducted in-depth market assessments for biopharmaceutical clients. She holds a Ph.D. in Cellular and Molecular Immunology and an M.Sc. in Molecular Biology from the Max Planck Research School in Germany. Her doctoral research focused on signalling pathways downstream of the B-cell antigen receptor.

Glenda Walker, Ph.D.

Senior Healthcare Research & Data Analyst – Oncology

Dr. Walker is a pharmaceutical industry analyst with more than 12 years' experience, preceded by 3.5 years as a journals editor. She has authored thought leadership articles covering a broad range of pharmaceutical industry-relevant topics and therapeutic areas, including the flagship Drugs to Watch article. She holds a Ph.D. in cell biology and genetics from the University of Manchester, and was a Wellcome postdoctoral fellow at the University College London Institute of Healthy Ageing, where she used microarray approaches to investigate key proteins involved in development and aging.